Spots Global Cancer Trial Database for polycythemia vera
Every month we try and update this database with for polycythemia vera cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Myeloproliferative Neoplasms: an In-depth Case-control Study | NCT01831635 | Polycythemia Ve... Essential Throm... Primary Myelofi... | Methodological ... Methodological ... Methodological ... | 18 Years - | Queen's University, Belfast | |
| Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms | NCT02823184 | Polycythemia Ve... Essential Throm... | RNA sample of t... | 18 Years - | University Hospital, Bordeaux | |
| Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera | NCT01949805 | Polycythemia Ve... | Peg-P-IFN-alpha... Hydroxyurea | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| Safety Evaluation Study for Patients With Polycythemia Vera | NCT05074550 | Polycythemia Ve... | PPMX-T003 | 20 Years - 75 Years | Perseus Proteomics Inc. | |
| Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients | NCT02893410 | Polycythemia Ve... Essential Throm... | 18 Years - | University Hospital, Brest | ||
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | NCT00003619 | Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni... | filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo... | 19 Years - 90 Years | National Cancer Institute (NCI) | |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia | NCT01998828 | Polycythemia Ve... Essential Throm... | Momelotinib | 18 Years - | Sierra Oncology LLC - a GSK company | |
| Study to Assess SLN124 in Patients With Polycythemia Vera | NCT05499013 | Polycythemia Ve... | SLN124 Placebo | 18 Years - | Silence Therapeutics plc | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | NCT04629508 | Myelofibrosis Polycythemia Ve... Thrombocythemia | itacitinib | 18 Years - | Incyte Corporation | |
| Study to Assess SLN124 in Patients With Polycythemia Vera | NCT05499013 | Polycythemia Ve... | SLN124 Placebo | 18 Years - | Silence Therapeutics plc | |
| MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | NCT05269771 | Polycythemia Ve... | Ruxolitinib | 12 Years - 99 Years | Novartis | |
| Familial Myeloproliferative Disorders | NCT00666289 | Polycythemia Ve... Essential Throm... Idiopathic Myel... | 7 Years - | Icahn School of Medicine at Mount Sinai | ||
| Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia | NCT02407080 | Polycythemia Ve... Essential Throm... | RG7388 Pegasys | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis. | NCT05993065 | Polycythemia Ve... | 18 Years - | Sohag University | ||
| A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | NCT01981850 | Primary Myelofi... Polycythemia Ve... Post-Essential ... | RO7490677 Ruxolitinib | 18 Years - | Hoffmann-La Roche | |
| Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | NCT00475020 | Myelofibrosis | Busulfan Fludarabine Thymoglobulin (... | - 75 Years | M.D. Anderson Cancer Center | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | NCT00132015 | Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co... | tanespimycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders | NCT00665067 | Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | NCT00588991 | Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Chronic Myeloid... Chronic Myelomo... de Novo Myelody... Essential Throm... Hematopoietic a... Myelodysplastic... Polycythemia Ve... Recurrent Adult... Recurrent Adult... Secondary Myelo... | Carboplatin Laboratory Biom... Topotecan Hydro... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 1 Study of XL019 in Adults With Polycythemia Vera | NCT00595829 | Polycythemia Ve... | XL019 | 18 Years - | Exelixis | |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | NCT02292446 | Polycythemia Ve... | Ruxolitinib | 18 Years - | Novartis | |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | NCT06218628 | Primary Myelofi... Post-polycythem... Post-essential ... Chronic Myelomo... Polycythemia Ve... Essential Throm... | Talazoparib pacritinib | 18 Years - | Fox Chase Cancer Center | |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | NCT02805868 | Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni... | Bone Marrow Asp... Laboratory Biom... Siltuximab | 18 Years - | Northwestern University | |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | NCT00038675 | Chronic Myelomo... Chronic Myeloid... Polycythemia Ve... Hypereosinophil... Mastocytosis | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders | NCT00665067 | Myeloproliferat... Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia | NCT03972943 | CALR Gene Mutat... Essential Throm... JAK2 Gene Mutat... MPL Gene Mutati... Obstructive Sle... Polycythemia Ve... | Continuous Posi... Patient Observa... Questionnaire A... | 30 Years - 85 Years | University of Utah | |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | NCT00445744 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child... | cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema... | - 65 Years | Fred Hutchinson Cancer Center | |
| The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV | NCT03003325 | Polycythemia Ve... | AOP2014 Phlebotomies ASA | 18 Years - 60 Years | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | |
| The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV | NCT03003325 | Polycythemia Ve... | AOP2014 Phlebotomies ASA | 18 Years - 60 Years | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| CC-4047 in Treating Patients With Myelofibrosis | NCT00669578 | Chronic Myelopr... Secondary Myelo... | CC-4047 | 18 Years - 120 Years | Mayo Clinic | |
| Pomalidomide for Myelofibrosis Patients | NCT00946270 | Polycythemia Ve... Thrombocythemia | CC-4047 Prednisone CC-4047 | 18 Years - | M.D. Anderson Cancer Center | |
| Myeloproliferative Neoplastic Diseases Observatory From Brest | NCT02897297 | Polycythemia Ve... Essential Throm... Primary Myelofi... | - | University Hospital, Brest | ||
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | NCT02311569 | Myeloproliferat... Primary Myelofi... Essential Throm... Polycythemia Ve... | Mirabegron | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | NCT02252159 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients | NCT01970930 | Polycythemia Ve... Essential Throm... | Blood specimen | - | Icahn School of Medicine at Mount Sinai | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| A Phase 1 Study of XL019 in Adults With Polycythemia Vera | NCT00595829 | Polycythemia Ve... | XL019 | 18 Years - | Exelixis | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythrocytosis. | NCT05993065 | Polycythemia Ve... | 18 Years - | Sohag University | ||
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | NCT04896112 | Acute Myeloid L... Primary Myelofi... Post-polycythem... Post-essential ... Polycythemia Ve... | LNK01002 | 18 Years - 99 Years | Lynk Pharmaceuticals Co., Ltd | |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | NCT04057040 | Polycythemia Ve... | PTG-300 Placebo | 18 Years - | Protagonist Therapeutics, Inc. | |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | NCT01520220 | Myeloproliferat... Polycythemia Ve... Essential Throm... Myelofibrosis | LY2784544 | 18 Years - | Eli Lilly and Company | |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera | NCT01243073 | Essential Throm... Polycythemia Ve... | Imetelstat | 18 Years - | Geron Corporation | |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | NCT06361641 | Myeloproliferat... Polycythemia Ve... Essential Throm... Primary Myelofi... | Monocytes signa... | 18 Years - | University Hospital, Angers | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Safety Study of XL019 in Adults With Myelofibrosis | NCT00522574 | Myeloproliferat... Myelofibrosis Polycythemia Ve... Thrombocythemia... | XL019 | 18 Years - | Exelixis | |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) | NCT04057040 | Polycythemia Ve... | PTG-300 Placebo | 18 Years - | Protagonist Therapeutics, Inc. | |
| Research Tissue Bank | NCT00666549 | Myelofibrosis Idiopathic Myel... Essential Throm... Polycythemia Ve... | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | NCT00038675 | Chronic Myelomo... Chronic Myeloid... Polycythemia Ve... Hypereosinophil... Mastocytosis | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation | |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | NCT01014546 | Essential Throm... Polycythemia Ve... Primary Myelofi... | Arsenic Trioxid... Ascorbic Acid Laboratory Biom... Pharmacological... | 19 Years - | Roswell Park Cancer Institute | |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | NCT00397813 | Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra... | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Natural Killer Cells and Polycythemia Vera (Vaquez's Disease) | NCT01284712 | Polycythemia Ve... | blood sample | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) | NCT01259856 | High Risk Polyc... High Risk Essen... | PEGASYS Hydroxyurea Aspirin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera | NCT00928707 | Polycythemia Ve... | GIVINOSTAT (ITF... GIVINOSTAT (ITF... | 18 Years - 80 Years | Italfarmaco | |
| Myeloproliferative Neoplasms and Bone Structure | NCT01816022 | Polycythemia Ve... Thrombocythemia... Primary Myelofi... | 18 Years - | University of Southern Denmark | ||
| A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera | NCT05210790 | Polycythemia Ve... | Placebo Rusfertide | 18 Years - | Protagonist Therapeutics, Inc. | |
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. | |
| Myeloproliferative Neoplastic Diseases Observatory From Brest | NCT02897297 | Polycythemia Ve... Essential Throm... Primary Myelofi... | - | University Hospital, Brest | ||
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | NCT01787552 | Primary Myelofi... Thrombocytosis Essential Throm... Polycythemia Ve... Myeloproliferat... Bone Marrow Dis... Hematologic Dis... Blood Coagulati... Blood Platelet ... Hemorrhagic Dis... | LDE225 INC424 | 18 Years - | Novartis | |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera | NCT04644211 | Essential Throm... Polycythemia Ve... | Ruxolitinib | 18 Years - | Massachusetts General Hospital | |
| Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera | NCT06033586 | Polycythemia Ve... | Open-label rusf... | 18 Years - | Protagonist Therapeutics, Inc. | |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | NCT05548062 | Polycythemia Ve... | Hydroxyurea Ruxolitinib | 18 Years - 99 Years | Novartis | |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis | NCT00745550 | Myelofibrosis Myeloproliferat... Polycythemia Ve... Essential Throm... | SB1518 | 18 Years - | S*BIO | |
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | NCT01243944 | Polycythemia Ve... | ruxolitinib tab... Best Available ... | 18 Years - | Incyte Corporation | |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | NCT01167166 | Acute Myelocyti... Acute Lymphocyt... Myeloproliferat... Chronic Myeloid... | rigosertib | 18 Years - | Traws Pharma, Inc. | |
| Imatinib Mesylate in Treating Patients With Myelofibrosis | NCT00039416 | Chronic Myelomo... Essential Throm... Polycythemia Ve... Primary Myelofi... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | NCT01632904 | Polycythemia Ve... | Ruxolitinib Hydroxyurea (HU... HU-placebo Ruxolitinib-pla... | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
